Integrated computational analyses nominated AKT1, CTNNB1, and GSK3β as potential therapeutic targets of ginkgetin in lung cancer, consistent with observed reductions in p-AKT and total GSK-3β alongside elevated p-GSK-3β levels post-treatment, thus experimental validation remains essential to determine whether modulation occurs via direct binding [53]. The gene discussed is GSK3B; the disease is lung cancer.